Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
18,277
Total Claims
$2.0M
Drug Cost
917
Beneficiaries
$2,216
Cost/Patient
Risk Score Breakdown 24/100
Score components are additive. Read full methodology
Peer Comparison vs. 44,021 Emergency Medicine providers
-77%
Opioid rate vs peers
2.2% vs 9.4% avg
+713%
Brand preference vs peers
12.1% vs 1.5% avg
⚠️ This provider has metrics more than 3 standard deviations above their specialty average in one or more categories.
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
2.2%
Opioid Rate
397
Opioid Claims
$6,217
Opioid Cost
—
Long-Acting Rate
Brand vs Generic
Brand: 2,184 claims · $1.7M
Generic: 15,922 claims · $333K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Semaglutide | 166 | $207K |
| Apixaban | 163 | $137K |
| Dulaglutide | 77 | $122K |
| Empagliflozin | 96 | $108K |
| Dapagliflozin Propanediol | 78 | $91K |
| Rivaroxaban | 94 | $86K |
| Insulin Glargine,hum.Rec.Anlog | 97 | $84K |
| Insulin Detemir | 68 | $67K |
| Empagliflozin/Metformin Hcl | 77 | $65K |
| Fluticasone/Umeclidin/Vilanter | 52 | $56K |
| Sitagliptin Phos/Metformin Hcl | 30 | $39K |
| Insulin Degludec | 29 | $39K |
| Insulin Glargine,hum.Rec.Anlog | 29 | $32K |
| Sitagliptin Phos/Metformin Hcl | 24 | $31K |
| Insulin Glargine,hum.Rec.Anlog | 16 | $31K |
Prescribing Profile
Patient Profile
73
Avg Age
54%
Female
1.39
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data